Table 1.
Demographics and the distribution of IDO expression
| Variable | Total N (%) |
IDO expression |
|
|---|---|---|---|
| Mean | P-value | ||
|
Age, years |
121 |
|
|
| <50 |
85 (70.2) |
7.0 |
<0.001 |
| ≥50 |
36 (29.8) |
20.2 |
|
|
Sex |
121 |
|
|
| Female |
41 (33.9) |
7.4 |
<0.001 |
| Male |
80 (66.1) |
12.8 |
|
|
Histologic subtype |
121 |
|
|
| NLP |
5 (4.1) |
3.3 |
<0.001 |
| NS |
64 (52.9) |
5.8 |
|
| MC |
46 (38.0) |
19.2 |
|
| LD |
1 (0.8) |
15.6 |
|
| LR |
1 (0.8) |
1.1 |
|
| Unclassifiable |
4 (3.3) |
8.9 |
|
|
Ann Arbor stage |
115 |
|
|
| I-II |
66 (57.4) |
6.9 |
0.004 |
| III-IV |
49 (42.6) |
17.3 |
|
|
B symptoms |
107 |
|
|
| Yes |
34 (31.8) |
16.2 |
0.454 |
| No |
73 (68.2) |
9.1 |
|
|
Bulky disease |
104 |
|
|
| Yes |
8 (7.7) |
11.8 |
0.826 |
| No |
96 (92.3) |
11.8 |
|
|
IPS |
116 |
|
|
| ≤2 |
82 (70.7) |
7.5 |
0.013 |
| >2 |
34 (29.3) |
20.6 |
|
|
EBV status |
96 |
|
|
| Positive |
43 (44.8) |
17.4 |
0.069 |
| Negative |
53 (55.2) |
8.7 |
|
|
HIV status |
121 |
|
|
| Positive |
3 (2.5) |
58.6 |
0.001 |
| Negative |
118 (97.5) |
9.7 |
|
|
Treatment response |
98 |
|
|
| Success |
65 (66.3) |
10.0 |
0.098 |
| Relapse |
21 (21.4) |
11.0 |
|
| Progression | 12 (12.2) | 26.4 | |
IDO, indoleamine 2,3-dioxygenase; NLP, nodular lymphocyte predominant; NS, nodular sclerosis; MC, mixed cellularity; LR, lymphocyte-rich; LD, lymphocyte-depleted; IPS, international prognostic score.